- Home
- APGE vs IDYA Comparison
APGE vs IDYA Comparison
Compare APGE & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- IDYA
- Stock Information
- Founded
- APGE 2022
- IDYA 2015
- Country
- APGE United States
- IDYA United States
- Employees
- APGE N/A
- IDYA N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- APGE Health Care
- IDYA Health Care
- Exchange
- APGE Nasdaq
- IDYA Nasdaq
- Market Cap
- APGE 2.1B
- IDYA 1.5B
- IPO Year
- APGE 2023
- IDYA 2019
- Fundamental
- Price
- APGE $37.81
- IDYA $18.18
- Analyst Decision
- APGE Strong Buy
- IDYA Strong Buy
- Analyst Count
- APGE 4
- IDYA 13
- Target Price
- APGE $91.33
- IDYA $53.58
- AVG Volume (30 Days)
- APGE 579.0K
- IDYA 1.5M
- Earning Date
- APGE 05-20-2025
- IDYA 05-06-2025
- Dividend Yield
- APGE N/A
- IDYA N/A
- EPS Growth
- APGE N/A
- IDYA N/A
- EPS
- APGE N/A
- IDYA N/A
- Revenue
- APGE N/A
- IDYA $7,000,000.00
- Revenue This Year
- APGE N/A
- IDYA $121.20
- Revenue Next Year
- APGE $743.14
- IDYA $302.20
- P/E Ratio
- APGE N/A
- IDYA N/A
- Revenue Growth
- APGE N/A
- IDYA N/A
- 52 Week Low
- APGE $26.20
- IDYA $13.45
- 52 Week High
- APGE $63.50
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- APGE 53.99
- IDYA 48.15
- Support Level
- APGE $36.59
- IDYA $16.82
- Resistance Level
- APGE $41.05
- IDYA $21.43
- Average True Range (ATR)
- APGE 2.25
- IDYA 1.19
- MACD
- APGE 0.15
- IDYA -0.06
- Stochastic Oscillator
- APGE 62.72
- IDYA 29.65
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.